Skip to main content

Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory or otorhinological infections: comparison with the results obtained from organisms isolated about 10 years ago

Abstract

The minimum inhibitory concentrations (MICs) of tosufloxacin and other fluoroquinolone antimicrobials for Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella (Branhamella) catarrhalis, isolated, between January 2003 and July 2004, from patients suspected of having respiratory or otorhinological infections were determined. The results were compared with those for these organisms isolated in 1994, plus some H. influenzae strains isolated in 1998. Tosufloxacin was the most potent of all the antibiotics tested for antibacterial activity against S. pneumoniae (including penicillin-intermediate S. pneumoniae and penicillin-resistant S. pneumoniae). The MIC50 and MIC90 values did not differ from those obtained for the strains isolated in 1994. Fluoroquinolones exerted the most potent antibacterial activity against M. (B.) catarrhalis; the MICs for most of the strains were ≦0.06 μg/ml; fluoroquinolones inhibited the growth of all the strains at 0.25 μg/ml or less. Fluoroquinolones showed the most potent antibacterial activity against H. influenzae strains isolated between 2003 and 2004, and in 1994, but, for one H. influenzae strain isolated, between 2003 and 2004, the MICs of fluoroquinolones were high. Some strains of S. pneumoniae and H. influenzae were resistant to fluoroquinolones. Genetic analysis showed that all of these strains had mutations in the quinolone resistance-determining region, but there were no differences according to the years of isolation. These results indicate that tosufloxacin has potent antibacterial activity against major organisms isolated from patients with respiratory or otorhinological infections; further, the results of the present study did not differ from those obtained about 10 years ago.

This is a preview of subscription content, access via your institution.

References

  1. K Fujimaki T Noumi Y Hamana S Mitsuhashi M Inoue (1988) ArticleTitleAntibacterial activity of T-3262 Chemother (Japan) 36 IssueIDS-9 1–18 Occurrence Handle1:CAS:528:DyaL1MXhsVOhtbo%3D

    CAS  Google Scholar 

  2. K Matsuzaki E Watabe K Yoshimori M Shikano Y Sato M Hasegawa et al. (2002) ArticleTitleAntibacterial activity of gatifloxacin against various fresh clinical isolates in 2002 Jpn J Antibiot 55 800–7 Occurrence Handle12621734

    PubMed  Google Scholar 

  3. Y Sato K Matsuzaki H Muraoka T Saika M Hasegawa I Kobayashi (2005) ArticleTitleAntimicrobial activity surveillance of various clinical isolates to tosufloxacin and other fluoroquinolones Jpn J Chemother 53 364–70 Occurrence Handle1:CAS:528:DC%2BD2MXmtVCit78%3D

    CAS  Google Scholar 

  4. InstitutionalAuthorNameNational Committee for Clinical Laboratory Standards (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. Sixth ed. M7-A6 NCCLS Wayne, PA

    Google Scholar 

  5. InstitutionalAuthorNameNational Committee for Clinical Laboratory Standards (2004) Performance standards for antimicrobial susceptibility testing; fourteenth informational supplement M100-S14 NCCLS Wayne, PA

    Google Scholar 

  6. C Janoir V Zeller MD Kitzis NJ Moreau L Gutmann (1996) ArticleTitleHigh-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA Antimicrob Agents Chemother 40 2760–4 Occurrence Handle9124836 Occurrence Handle1:CAS:528:DyaK28Xnt1GnsLw%3D

    PubMed  CAS  Google Scholar 

  7. XS Pan J Ambler S Mehtar LM Fisher (1996) ArticleTitleInvolvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae Antimicrob Agents Chemother 40 2321–6 Occurrence Handle8891138 Occurrence Handle1:CAS:528:DyaK28XmtVCgtrc%3D

    PubMed  CAS  Google Scholar 

  8. B Perichon J Tankovic P Courvalin (1997) ArticleTitleCharacterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae Antimicrob Agents Chemother 41 1166–7 Occurrence Handle9145891 Occurrence Handle1:CAS:528:DyaK2sXjtVCktbc%3D

    PubMed  CAS  Google Scholar 

  9. TA Davies LM Kelly DB Hoellman LM Ednie CL Clark S Bajaksouzian et al. (2000) ArticleTitleActivities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis Antimicrob Agents Chemother 44 633–9 Occurrence Handle10681330 Occurrence Handle1:CAS:528:DC%2BD3cXhsVGhu74%3D Occurrence Handle10.1128/AAC.44.3.633-639.2000

    PubMed  CAS  Article  Google Scholar 

  10. S Kohno K Yanagihara A Saito M Tateyama T Matsushima Y Niki et al. (2005) ArticleTitleThe efficacy of tosufloxacin tosilate against Streptococcus pneumoniae community-acquired pneumonia Jpn J Chemother 53 11–19

    Google Scholar 

  11. H Kobayashi K Hara J Kumazawa (1997) ArticleTitlePhase II a study of injectable ciprofloxacin Jpn J Chemother 45 820–32

    Google Scholar 

  12. S Yokota K Sato S Yoshida N Fujii (2004) ArticleTitleMolecular epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae in Japan Kansenshogaku Zasshi 78 428–34 Occurrence Handle15211865

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Intetsu Kobayashi.

About this article

Cite this article

Hasegawa, M., Sato, Y., Kanayama, A. et al. Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory or otorhinological infections: comparison with the results obtained from organisms isolated about 10 years ago. J Infect Chemother 12, 152–156 (2006). https://doi.org/10.1007/s10156-006-0434-2

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10156-006-0434-2

Key words

  • Tosufloxacin
  • Antimicrobial activity
  • Clinical isolate
  • Drug resistance
  • Respiratory tract infection